


## NH-bis(C2-PEG2-NH-Boc)

|                    |   |       |          |
|--------------------|---|-------|----------|
| Cat. No.:          | HY-130531   |       |          |
| CAS No.:           | 2182601-69-8  |       |          |
| Molecular Formula: | C <sub>22</sub> H <sub>45</sub> N <sub>3</sub> O <sub>8</sub> |       |          |
| Molecular Weight:  | 479.61  |       |          |
| Target:            | PROTAC Linkers  |       |          |
| Pathway:           | PROTAC  |       |          |
| Storage:           | Pure form   | -20°C | 3 years  |
|                    |   | 4°C   | 2 years  |
|                    | In solvent  | -80°C | 6 months |
|                    |   | -20°C | 1 month  |



### BIOLOGICAL ACTIVITY

|                           |  |             |  |
|---------------------------|--|-------------|--|
| Description               | NH-bis(C2-PEG2-NH-Boc) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs <sup>[1]</sup> .  |             |  |
| IC <sub>50</sub> & Target | PEGs   | Alkyl/ether |  |
| In Vitro                  | PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |             |  |

### REFERENCES

[1]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. *EBioMedicine*. 2018 Oct;36:553-562

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA